Effects of reduced dialysate calcium on calcium-phosphorus product and bone metabolism in Hemodialysis patients

被引:14
作者
Fiedler, R
Deuber, HJ
Langer, T
Osten, B
Mohan, S
Jehle, PM
机构
[1] Univ Halle Wittenberg, Div Nephrol, Dept Nephrol, DE-06097 Halle An Der Saale, Germany
[2] KfH Dialysis Ctr, Zirndorf, Germany
[3] St Elizabeth Hosp, Dept Internal Med 1, Halle An Der Saale, Germany
[4] Jerry L Pettis Mem Vet Adm Med Ctr, Musculoskeletal Dis Ctr 151, Loma Linda, CA 92354 USA
[5] Paul Gerhardt Fdn Hosp, Lutherstadt Wittenberg, Germany
来源
NEPHRON CLINICAL PRACTICE | 2004年 / 96卷 / 01期
关键词
reduced dialysate calcium; calcium-phosphorus product; parathyroid hormone; noninvasive bone markers; IGF system components;
D O I
10.1159/000075565
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: The safety of using reduced calcium dialysate (RDC) in hemodialysis (HD) patients is controversial due to related changes in bone metabolism. In the present study we investigated whether an 18-month treatment period with RDC may induce significant changes in calcium-phosphorus product (CaxP), bone metabolism, and components of the insulin-like growth factor (IGF) system in HD patients. Study Design: In this prospective study, 13 HD patients with biochemical signs of diminished or low-normal bone turnover and high CaxP due to high serum calcium level were treated by lowering dialysate calcium from 3.5 to 2.5 mEq/l for 18 months. By specific immunometric assays, serum levels of intact parathyroid hormone (PTH), bone alkaline phosphatase (B-ALP), pyridinoline (PYR), desoxypyridinoline (D-PYR), 25-OH-vitamin D-3 (25-vit D-3), 1,25-(OH)(2)-vitamin D-3 (1,25-vit D-3), free IGF-I, IGF-II, and IGF-binding protein (IGFBP)-1 to -6 were measured. Results: CaxP decreased significantly from 5.62 (baseline) to 3.95 mmol(2)/l(2) (at 18 months), whereas PTH increased from 81 +/- 57 pg/ml at baseline to 236 +/- 188 at 12 months (p < 0.01), remaining in this range thereafter. Parameters of bone resorption (PYR) as well as formation (B-ALP) significantly increased during RDC, with peak levels after 12 months. Despite increasing doses of oral alfacalcidol, levels of 25-vit D-3 and 1,25-vit D-3 subsequently declined during RDC. In parallel with the changes in bone markers, free IGF-I levels decreased (baseline: 1.9 +/- 0.9 ng/ml, after 18 months: 1.1 +/- 0.7; p < 0.01). The decline of free IGF-I correlated with decreasing levels of IGFBP-3 and increasing levels of IGFBP-1/-4. Conclusion: The treatment with RDC effectively lowered CaxP and stimulated bone formation and resorption. The different changes in bone markers and IGF system components mirror the complex effects on bone metabolism. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:C3 / C9
页数:7
相关论文
共 47 条
  • [1] Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism
    Abdelhadi, M
    Nordenstrom, J
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (11) : 3845 - 3851
  • [2] Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor
    Andress, DL
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1998, 274 (04): : E744 - E750
  • [3] PLASMA INSULIN-LIKE GROWTH-FACTORS AND BONE-FORMATION IN UREMIC HYPERPARATHYROIDISM
    ANDRESS, DL
    PANDIAN, MR
    ENDRES, DB
    KOPP, JB
    [J]. KIDNEY INTERNATIONAL, 1989, 36 (03) : 471 - 477
  • [4] ANDRESS DL, 1992, J BIOL CHEM, V267, P22467
  • [5] CALCIUM KINETICS AND THE LONG-TERM EFFECTS OF LOWERING DIALYSATE CALCIUM-CONCENTRATION
    ARGILES, A
    KERR, PG
    CANAUD, B
    FLAVIER, JL
    MION, C
    [J]. KIDNEY INTERNATIONAL, 1993, 43 (03) : 630 - 640
  • [6] CHRONIC METABOLIC-ACIDOSIS DECREASES ALBUMIN SYNTHESIS AND INDUCES NEGATIVE NITROGEN-BALANCE IN HUMANS
    BALLMER, PE
    MCNURLAN, MA
    HULTER, HN
    ANDERSON, SE
    GARLICK, PJ
    KRAPF, R
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (01) : 39 - 45
  • [7] A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients
    Bleyer, AJ
    Burke, SK
    Dillon, M
    Garrett, B
    Kant, KS
    Lynch, D
    Rahman, SN
    Schoenfeld, P
    Teitelbaum, I
    Zeig, S
    Slatopolsky, E
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (04) : 694 - 701
  • [8] Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study
    Block, GA
    Hulbert-Shearon, TE
    Levin, NW
    Port, FK
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) : 607 - 617
  • [9] THE CONTRIBUTION OF ACIDOSIS TO RENAL OSTEODYSTROPHY - DISCUSSION
    BUSHINSKY, DA
    MADIAS, NE
    HARRINGTON, JT
    KING, A
    LEMAY, S
    PARKER, M
    [J]. KIDNEY INTERNATIONAL, 1995, 47 (06) : 1816 - 1832
  • [10] THE ROLE OF 1,25-DIHYDROXYVITAMIN-D IN THE MECHANISM OF ACQUIRED VITAMIN-D DEFICIENCY
    CLEMENTS, MR
    DAVIES, M
    HAYES, ME
    HICKEY, CD
    LUMB, GA
    MAWER, EB
    ADAMS, PH
    [J]. CLINICAL ENDOCRINOLOGY, 1992, 37 (01) : 17 - 27